Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Sorrento now has the exclusive rights to rapidly produce C1 based Covid vaccines for 60% (SIXTY) of the world's population. Sorrento can immediately use existing manufacturing facilities in the US and China. The multi-variant vaccine can be cheaply produced and shipped and stored without a costly cold-chain. North and South America, Europe, China, Japan and other parts of Asia can all now be reached with an affordable, more effective, alternative to costly first generation cold-chain shackled mRNA vaccines.

Sorrento now can offer highly accurate affordable testing(COVISTIX),early treatment(COVIDROPS), cytokine storm prevention(ABIVERTINIB), late stage ICU rescue(COVIMSC) and long haul treatment(ARD-301). These are all potential EUA candidates and the Mexican EUA approval is only the first of many. The addition of two vaccine candidates (multi-variant C1 and multi-variant second generation mRNA) only strengthens the 15 item Covid portfolio.